| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Dermatology, Kanazawa University School of Medicine, Kanazawa, Japan; and
Department of Immunology, Duke University Medical Center, Durham, NC 27710
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
20%) higher compared with normal individuals,
whereas CD20, CD22, and CD40 expression were normal. These results
suggest that modest changes in the expression or function of regulatory
molecules such as CD19 may shift the balance between tolerance and
immunity to autoimmunity. Thereby autoimmune disease may result from a
collection of subtle multigenic alterations that could include
incremental density changes in cell surface signaling
molecules. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
CD19 is a B cell-specific member of the Ig superfamily expressed by early pre-B cells from the time of heavy chain rearrangement until plasma cell differentiation. The cell surface density of CD19 is tightly regulated during B cell differentiation, particularly in mice (10, 11). After B cell maturation, cellular activation induced by various stimuli, such as anti-IgM Abs, LPS, and IL-4, does not affect CD19 expression in either mice or humans (4, 12). Nonetheless, the B1 subset of mouse B cells expresses CD19 at levels 60% higher than conventional B cells (4). Mouse lines that overexpress CD19 have been generated by the B cell-specific expression of a human CD19 (hCD19)4 transgene (13). Since hCD19 and mouse CD19 (mCD19) are functionally equivalent in vivo when expressed at comparable site densities (11), these different mouse lines express overall CD19 at various cell surface densities. In these mice, CD19 expression levels correlate directly with altered B cell function, B cell hyperactivity, and autoantibody production (4, 11). Dose-dependent changes in B cell development and function resulting from CD19 overexpression in vivo presumably result from the fact that the cytoplasmic domain of CD19 is a central regulatory component of B cells upon which multiple signaling pathways converge (2). Perhaps most important, CD19 regulates a Src family protein tyrosine kinase activation loop in resting and Ag receptor-stimulated B cells that establishes basal signaling thresholds (14, 15).
Since previous "gene titration" studies in mice have shown that 2- or 3-fold increases in CD19 expression can predispose mice to autoantibody production, we assessed whether more subtle changes in CD19 expression could alter B cell homeostasis. Remarkably, a genetically determined quantitative increase in CD19 expression by 15–29% induced autoantibody production in mice that are otherwise genetically wild-type. CD19 expression was also 20% higher on B cells from autoimmune patients with systemic sclerosis (SSc) compared with healthy individuals. Therefore, it is possible that modest alterations in CD19 function or expression contribute to the development of autoimmunity. Moreover, similar subtle alterations in the expression or function of other important regulatory molecules may predispose to autoimmune susceptibility in other syndromes.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
hCD19-transgenic (TG)-1 (C57BL/6 x B6/SJL) mice and hCD19TG-4 (C57BL/6 x B6/SJL) mice were described previously (13). hCD19TG-1 (C57BL/6 x B6/SJL) mice were backcrossed with C57BL/6 mice for either 7 or 12 generations before use in these studies. The hCD19TG-1 line backcrossed with C57BL/6 mice for seven generations overexpresses CD19 by 2.6-fold (4, 11). However, the hCD19TG-1 line backcrossed with C57BL/6 mice for 12 generations expressed hCD19 at levels similar to human blood B cells and thereby only overexpressed CD19 by 2-fold (data not shown). The molecular basis for the decrease in hCD19 expression in the hCD19TG-1 line is unknown. Reduced hCD19 expression could have resulted from a decrease in the number of hCD19 gene copies in this line of mice or subtle genetic changes. Nonetheless, hCD19TG-1 mice that were backcrossed with C57BL/6 mice for 12 generations and overexpress CD19 by 2-fold were used as positive controls for the current experiments unless noted otherwise. Wild-type littermates generated from breedings of hemizygous transgenic mice were used as negative controls. Results with wild-type littermates of hCD19TG-1 and hCD19TG-4 mice were similar and were therefore pooled. All mice were between 2 and 3 mo of age when used for this study. Mice were housed in a specific pathogen-free barrier facility. All mice were regularly checked for infections, pathogens, and parasites by clinical veterinarians. All tests have been negative for >3 years. All studies and procedures were approved by the Committee on Animal Experimentation of Kanazawa University School of Medicine and the Animal Care and Use Committee of Duke University.
Flow cytometric analysis
Abs used in these studies included the anti-mCD19 mAbs, rat IgG2a clone 6D5 (Caltag, Burlingame, CA), and mouse IgA clone MB19-1 (4). Antihuman Abs used in this study included PE- or FITC-conjugated anti-hCD19 (B4), anti-CD20 (HRC20), anti-CD21 (B2), anti-CD22 (B3), anti- CD40 (MAB89; Coulter, Miami, FL), and anti-hCD19 mAbs (mouse IgG1 clone SJ25-C1; Caltag). For immunofluorescence staining, fresh heparinized whole blood samples were placed on ice immediately after collection. Blood samples (50 µl) were stained at 4°C using predetermined saturating concentrations of the test mAb for 20 min as previously described (11, 16). Blood erythrocytes were lysed after staining using the Coulter Whole Blood Immuno-Lyse kit as detailed by the manufacturer (Coulter). Cells were analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA). Five thousand cells with the forward and side light scatter properties of mononuclear cells were analyzed for each sample, with fluorescence intensity shown on a four-decade log scale. Fluorescence contours are shown as 50% log density plots. Positive and negative populations of cells were determined using unreactive isotype-matched mAbs (Coulter) as controls for background staining. Background levels of staining were delineated using gates positioned to include 98% of the control cells.
CD19 expression density assessment
Cell surface densities of hCD19 and mCD19 were determined by staining blood lymphocytes using PE-conjugated anti-mCD19 (6D5) and anti-hCD19 (SJ25-C1) mAbs. The two Ab preparations had fluorochrome:Ab molar ratios of 1.0. After direct immunofluorescence staining and flow cytometry analysis, the number of PE molecules bound on the surface of CD19+ lymphocytes was determined using the QuantiBRITE PE Fluorescence Quantitation kit (Becton Dickinson Immunocytometry Systems, San Jose, CA) and software provided by the manufacturer. The PE Fluorescence Quantitation kit provides beads conjugated with four levels of PE that are used to generate a standard curve by flow cytometry analysis. Linear regression analysis is then used to determine the number of PE molecules bound to mAb-stained cells during flow cytometry analysis. Lymphocytes were incubated with various concentrations of the test mAb for 40 min at 4°C immediately before flow cytometry analysis. The percentage of CD19+ cells among lymphocytes in each sample was determined by flow cytometry analysis with total cell numbers determined using a hemocytometer. For Scatchard analysis (17), the number of cell-bound PE-mAb molecules was determined by calculating the total number of cell-bound PE molecules per sample for comparison with the total number of mAb molecules added to each sample. The maximal binding capacity of each mAb preparation was determined as described (18).
Mouse Ig isotype-specific ELISAs
ELISAs were conducted as described previously using affinity-purified mouse IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA Abs (Southern Biotechnology Associates, Birmingham, AL) to generate a standard curve (19, 20). The relative concentration of each Ig isotype in individual samples was calculated by comparing the mean OD value obtained for duplicate wells to a semilog standard curve of titrated standard Ab using linear regression analysis.
Antinuclear Ab (ANA) analysis
ANA was assayed by indirect immunofluorescence staining with
sera diluted 1:50 using HEp-2 substrate cells (Medical & Biological
Laboratories, Nagoya, Japan) as described elsewhere (21).
Ig isotype-specific ANAs were performed using FITC-conjugated goat
F(ab')2 fragment anti-mouse IgG
(
-chain-specific), anti-mouse IgM (µ-chain-specific), and
anti-mouse IgG + IgM + IgA (Southern Biotechnology Associates) Abs.
For two-color immunofluorescence staining of mouse and human serum
samples, Ab binding was visualized using species-specific tetraethyl
sulforhodamine-conjugated goat F(ab')2
anti-mouse Ig Abs (BioSource International, Camarillo, CA) and
FITC-conjugated goat F(ab')2 anti-human Ig
Abs (Medical & Biological Laboratories).
ELISAs for autoantibodies
Serum autoantibody levels were determined by ELISA as described
previously (4). Briefly, 96-well microtiter plates
(Costar, Cambridge, MA) were coated overnight at 4°C with 5 µg/ml
ssDNA (Sigma, St. Louis, MO), dsDNA (MBL), histone (Sigma), or rabbit
IgG (Sigma). Plates were incubated for 1.5 h with serum samples
diluted 1:100 in TBS containing 1% BSA (Sigma). After washing three
times, the plates were incubated with peroxidase-conjugated goat
anti-mouse IgG (-chain-specific) or goat anti-mouse IgM
(µ-chain-specific) Abs (Southern Biotechnology Associates) for 1
h. Substrate solution containing 0.0125% o-phenylenediamine
(Sigma) and 0.015% H2O2 in
0.1 M sodium citrate buffer (pH 4.5) was added and the OD of the wells
was subsequently determined. Relative levels of autoantibodies were
determined for each group of mice using pooled serum samples. Sera were
diluted at log intervals (1:10–1:105) and
assessed for relative autoantibody levels as above, except the results
were plotted as OD vs dilution (log scale). The dilutions of sera
giving half-maximal OD values were determined by linear regression
analysis, thus generating arbitrary unit per milliliter values for
comparison between sets of sera.
SSc and systemic lupus erythematosus (SLE) patients
Nineteen patients (16 females and 3 males, 23–72 years old) who fulfilled the criteria for SSc proposed by the American College of Rheumatology (formerly the American Rheumatism Association) (22) were examined. Patients with SSc were grouped according to the classification system proposed by LeRoy et al. (23): 13 patients (10 females and 3 males) had limited cutaneous SSc and 6 (all female) had diffuse cutaneous SSc. None of the SSc patients had received oral steroids, D-penicillamine, or immunosuppressive drugs.
All patients with SLE fulfilled the criteria proposed by the American College of Rheumatology (24) and had active SLE as determined by the SLE Disease Activity Index (25) that ranged between 8 and 20 for these patients. Three patients had not been medicated and two patients had received low-dose steroids (prednisolone, 10–20 mg/day), but had disease relapses at the time of blood collection. None of the SLE patients had received immunosuppressive drugs. Thirty-two age- and sex-matched healthy volunteers served as normal controls for the SSc and SLE patients. Laboratory data (serum levels of IgM, IgG, IgA, CH50, C3, and C4, erythrocyte sedimentation rates, C-reactive protein, and ANA titer) and blood samples were obtained at the same time. The protocol was approved by the Kanazawa University School of Medicine, and informed consent was obtained from all patients.
Statistical analysis
All data are shown as mean values ± SD unless indicated otherwise. ANOVA was used to analyze the data and Student’s t test was used to determine the level of significance of differences in sample means.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Transgenic mouse lines expressing various cell surface densities of hCD19 have been previously described (13). Mice from the hCD19TG-1 line produce spontaneous autoantibodies (4, 5). Moreover, autoantibody production correlates with the level of CD19 overexpression and CD19 expression correlates directly with gene dosage such that heterozygous mice express half as much hCD19 as their homozygous littermates (4). The hCD19TG-1 line (backcrossed with C57BL/6 mice for seven generations) overexpresses CD19 by 2.6-fold based on comparisons of hCD19 expression between mouse and human blood B cells (4, 11). Since there are no mAbs that react with both mCD19 and hCD19, these comparisons are based on the assumption that mouse and human B cells express similar cell surface densities of CD19.
To correlate CD19 expression with autoantibody production, the number
of hCD19 and mCD19 molecules expressed on the surface of B cells in
CD19TG mouse lines was quantified by immunofluorescence staining with
saturating concentrations of IgG mAbs specific for hCD19 or mCD19. Two
lines of hCD19TG mice were used for these studies: hCD19TG-1 mice that
were backcrossed with C57BL/6 mice for seven generations (4, 11) and hCD19TG-4 mice that carry fewer copies of the hCD19
transgene. hCD19 was expressed by all B cells and only B cells among
hematopoietic cells from hCD19TG mice (Fig. 1
A). Cell surface hCD19
expression by blood B cells of hCD19TG-4+/- mice
was 22 ± 3% of that expressed by
hCD19TG-1+/- mice (n = 5; Fig. 1B). Hemizygous hCD19TG-1+/- mice
that were backcrossed with C57BL/6 mice for seven generations express
hCD19 at levels comparable to human blood B cells (4, 11).
Endogenous mCD19 expression in hCD19TG-4+/- mice
was 94 ± 2% (n = 5) of levels observed in
wild-type littermates (Fig. 1, A and B). Thus, if
circulating B cells from mice and humans express CD19 at comparable
site densities, overall CD19 expression levels in
hCD19TG-4+/- mice were 116 ± 5% of
wild-type mCD19 levels as determined by the intensity of
immunofluorescence staining.
|
C). B cells from hCD19TG1+/+
mice expressed 36,800 ± 1,520 sites and
hCD19TG-4+/- mice expressed 6,740 ± 170
mAb binding sites (Fig. 1C). Endogenous mCD19 expression was
assessed similarly; wild-type mice expressed 20,800 ± 570 sites,
hCD19TG1+/+ mice 16,600 ± 730 sites (80%
of wild-type), and hCD19TG-4+/- mice 20,000
± 410 (96% of wild-type) anti-mCD19 mAb binding sites (Fig. 1C). With a strict interpretation of these results,
hCD19TG-1+/+ and
hCD19TG-4+/- B cells expressed overall CD19 at
257 and 29% higher levels than their wild-type littermates,
respectively. Although these results suggest that human blood B cells
express CD19 at 70% higher levels than mouse B cells, variability
in ligand binding between the anti-hCD19 and anti-mCD19 mAb
could also explain these apparent differences. Therefore, if human and
mouse B cells express CD19 at comparable densities, then
hCD19TG-1+/+ and
hCD19TG-4+/- B cells express overall CD19 at 183
and 15% higher levels than their wild-type littermates, respectively.
Thus, hCD19TG-4+/- B cells overexpress CD19 by
15–29%. Effect of CD19 overexpression on B cell development
The effect of the small increase in CD19 expression on B cell
differentiation in hCD19TG-4+/- mice was
assessed by quantifying B cell numbers and measuring serum Ab levels.
Overall, the numbers of B cells found in
hCD19TG-4+/- mice and their wild-type
littermates were not significantly different, whereas peripheral B cell
numbers were significantly reduced in
hCD19TG-1+/+ mice (Table I). Despite apparently normal B cell
numbers in hCD19TG-4+/- mice, serum IgG1
(p < 0.05), IgG2a (p
< 0.05), and IgG2b (p < 0.001) levels were
significantly increased in hCD19TG-4+/- mice
when compared with wild-type littermates, while serum IgM, IgG3, and
IgA levels were normal (Fig. 2). Serum Ig
levels in hCD19TG-1+/+ mice were generally higher
than those in hCD19TG-4+/- mice, especially IgM,
IgG2a, and IgG2b. Serum Ig levels did not differ between males and
females (data not shown). Thus, small increases in CD19 expression
resulted in significantly increased production of selected serum Ab
isotypes in hCD19TG-4+/- mice. However, humoral
responses following immunizations with a T cell-dependent Ag were not
significantly increased in hCD19TG-4+/- mice
(data not shown).
|
|
Autoantibody levels in hCD19TG-4+/- mice
were determined to assess the influence of elevated CD19 expression.
ANAs were detected in 52% of hCD19TG-4+/- mice
and 95% of hCD19TG-1+/+ mice, but were rarely
detectable in wild-type littermates (Fig. 3; Table II). These autoantibodies were
predominantly of the IgG isotype. A homogenous chromosomal staining
pattern with more intense staining of mitotic cells was observed in
21% of the serum samples from hCD19TG-4+/- mice
(Fig. 3c). The frequency (86%) and intensity of homogenous
staining was higher for sera from hCD19TG-1+/+
mice (Fig. 3e). Sera from 28% of
hCD19TG-4+/- mice reacted with spindle poles
(mitotic centers) of mitotic cells (Fig. 3b), whereas this
staining pattern was observed in only 10% of sera from
hCD19TG-1+/+ mice (Fig. 3d).
Since human autoantibodies recognizing centrioles, which are components
of spindle poles, give a staining pattern similar to that observed for
some hCD19TG-4+/- sera (Fig. 3f; and Refs. 26, 27, 28), two-color
immunofluorescence staining was conducted with human anti-centriole
Ab-positive serum and sera from hCD19TG-4+/-
mice. Both the mouse and human sera stained similar intracellular
determinants, although the localized regions recognized by the mouse
serum were larger than those of the human anticentriole Abs (Fig. 3, f and g). The antispindle pole autoantibodies
stained mitotic cells, whereas the anticentriole Abs stained both
mitotic and interphase cells. Anticentromere Abs were not detected in
sera of hCD19TG-4+/- or
hCD19TG-1+/+ mice. The frequency, specificity,
and intensity of ANAs were similar between males and females (data not
shown). Thus, the predominant ANA specificity in
hCD19TG-4+/- sera was for spindle poles, while
homogenous staining was most commonly observed with
hCD19TG-1+/+ mouse sera.
|
|
). Mean IgG
anti-ssDNA (346% higher, p < 0.001),
anti-dsDNA (194% increase, p < 0.005), and
anti-histone (755% increase, p < 0.001)
autoantibody titers were significantly higher in
hCD19TG-4+/- mice. Mean IgM antihistone Ab
(142%, p < 0.05) and IgM rheumatoid factor (RF;
211%, p < 0.05) titers were also increased. Serum
levels of all autoantibody specificities in
hCD19TG-1+/+ mice were generally higher than
those in hCD19TG-4+/- mice. Anti-DNA
topoisomerase I Ab levels did not increase in either
hCD19TG-4+/- or
hCD19TG-1+/+ mice as quantified by ELISA (data
not shown).
|
Histopathological analysis of kidneys from 2- to 8-mo-old hCD19TG-4+/- mice showed a normal architecture without detectable Ab deposits (data not shown). Swelling or deformity of joints, skin eruptions, or a thickened dermis were not observed. Mortality in transgenic mice was similar to that of wild-type littermates. In the hCD19TG-1+/+ line of mice, there is a significant decrease in the reproductive capacity of female mice following birth of their first litter. However, none of the hCD19TG mice developed overt symptoms suggestive of lupus or scleroderma-like disease.
CD19 expression by B cells from SSc and SLE patients
Since small genetic changes in cell surface CD19 expression
induced autoantibody production in mice, B cells from autoimmune
patients with SSc and SLE were assessed for abnormal CD19 expression.
The cell surface density of CD19 on peripheral blood B cells from
patients and healthy control individuals was examined quantitatively by
immunofluorescence staining with flow cytometry analysis. SSc patients
had significantly higher mean CD19 expression levels than normal
controls (20%, p < 0.0001; Figs. 5 and 6 ).
Similarly, mean CD21 expression was 23% higher in SSc patients than in
normal controls (p < 0.001). However, there
was not a significant correlation between CD19 and CD21 expression in
SSc patients (n = 19, r = -0.07, Fig. 6A), although CD21 expression was significantly correlated
with CD19 expression in normal controls (n = 32,
r = 0.48, p < 0.01, Fig. 6A). CD19 and CD21 expression levels were similar in male
and female patients (data not shown). Mean CD20, CD22, and CD40
expression levels were similar in SSc patients and normal controls.
Higher CD19 expression in SSc patients did not result from increased
cell size since the forward and side light scatter properties of
CD20+ cells in SSc patients were not measurably
different from those of normal controls (data not shown). Elevated CD19
expression did not result from B cell activation since HLA-DR, CD25,
CD54, CD80, and CD86 expression levels were not increased on B cells
from SSc patients (data not shown). In contrast to SSc patients, CD19
and CD21 expression levels were reduced on B cells from SLE patients
(Fig. 6B). Limited numbers of samples were available for SLE
patients who had not undergone treatment or who had been in an active
state of the disease for only a short time period. Therefore, the
results obtained with these SLE patients may not represent a broader
SLE population since the clinical manifestations of SLE are
heterogeneous. Rather, the results with SLE patients are shown for
comparison to demonstrate that increased CD19 expression correlated
with SSc, but was not observed in other autoimmune diseases such as
SLE. Thus, elevated CD19 and CD21 expression levels were the primary
phenotypic abnormalities observed for B cells from SSc patients.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
) significantly increases
autoantibody production in mice (Figs. 3 and 4; Table II). Furthermore,
these results suggest that modest changes in the expression or function
of regulatory molecules in addition to CD19 may shift the balance
between tolerance and immunity to autoimmunity. Since most SSc patients
overexpressed CD19 to an extent comparable to the levels induced
genetically in hCD19TG4+/- mice, small changes
in CD19 expression might also contribute to human autoimmunity (Figs. 5 and 6). In addition, genetic changes that result in graded alterations
of B lymphocyte signaling thresholds may help explain why different
autoimmune diseases produce characteristic patterns of autoantibodies.
For example, CD19 expression levels in transgenic mice correlate
directly with an increased capacity for autoantibody production
(4), yet autoantibodies against spindle poles were
detected more frequently in hCD19TG-4+/- mice
than in hCD19TG-1+/+ mice (Table II). This
suggests that differing autoantibody specificities may result from
different "autoimmunity susceptibility gene" dosages or degrees of
B cell dysregulation during systemic autoimmunity. Thereby incremental
changes in the expression or function of important regulatory molecules
may qualitatively modify the specificity of autoantibodies as well as
amplify autoantibody production quantitatively.
The current gene titration studies suggest that genetically determined
quantitative changes in CD19 expression alone can induce autoantibody
production in a mouse genetic background not associated with
autoimmunity. Although hCD19TG mice do not produce autoantibodies at
levels equivalent to those found in other mouse models of spontaneous
autoimmune disease, the production of autoantibodies is nonetheless
remarkable given that most mouse models of autoimmunity result from
radical genetic defects or the introduction of Ag receptor transgenes
that dramatically alter the immune systems of the mice being studied
(29). Rather, subtle genetic alterations, like CD19
overexpression in this study, may more accurately reflect the genetic
basis for predisposition to autoimmunity. In addition, most mouse
models of autoimmunity do not accurately reflect the varied and complex
autoimmune syndromes found in humans. That increased expression of CD19
correlated with autoantibody production in SSc patients, but not in SLE
patients (Fig. 6) also follows, since different mechanisms are likely
to correlate with autoantibody production among the different
autoimmune disorders. Genetic alterations similar to increased CD19
expression may also explain why autoantibody specificities and clinical
manifestations are different among the autoimmune diseases. As with
most transgenic mouse lines, hCD19TG-1+/+ and
hCD19TG-4+/- mice originated in a (C57BL/6
x SJL)F1 genetic background (13).
It is therefore possible that background genes present in either of
these mouse strains complement increased CD19 expression. However,
wild-type offspring of hemizygous hCD19TG mice were similar to C57BL/6
mice and did not produce significant autoantibodies (Table II).
Moreover, that incremental doses of CD19 expression induced
autoantibody production in two independent lines of mice suggests that
CD19 overexpression is the major contributor to autoantibody production
in this mouse model. In addition, autoantibodies remain a feature of
the hCD19TG-1+/+ line even after being
backcrossed with C57BL/6 mice for 12 generations. Therefore, it is
likely that overexpression of CD19 in isolation can disrupt tolerance
and induce autoantibody production (5).
That a 15–29% increase in CD19 expression affects B cell function
affirms a significant regulatory role for CD19 (
Figs. 2–6). These
results are also consistent with the notion that cell surface CD19
expression levels are tightly regulated. In support of this, a major
regulatory function for CD22/SHP1 is to down-regulate CD19 tyrosine
phosphorylation following B cell Ag receptor engagement
(30). In addition, the CD19 cytoplasmic domain has
dose-dependent functional activities that appear independent of cell
surface engagement or signal transduction through other members of the
CD19 complex (31). The CD19 cytoplasmic region of 240
amino acids contains 9 conserved tyrosine residues which mediate its
interactions with Lyn, Lck, Fyn, phosphatidylinositol 3-kinase, and the
adapter proteins Vav, Cbl, Shc, and Grb2. Importantly, the CD19
cytoplasmic domain regulates an endogenous and Ag receptor-induced Src
family protein tyrosine kinase amplification loop that regulates Vav
phosphorylation and B cell signal transduction thresholds (14, 15). Since the CD19 cytoplasmic domain can up-regulate Src
family protein tyrosine kinase activity in isolation, it is likely that
small alterations in CD19 expression levels will have parallel affects
on Src family kinase activity within B cells. Consistent with this,
endogenous and Ag receptor-induced Lyn kinase activities and Vav
phosphorylation are up-regulated in B cells that overexpress CD19 by
3-fold and diminished in CD19-deficient B cells (15). We
were unable to quantitate significant alterations in B cell development
(Table I) or Lyn and Vav phosphorylation in B cells isolated from
hCD19TG-4+/- mice (data not shown). Similarly,
humoral immune responses were not significantly increased in
hCD19TG-4+/- mice (data not shown). Thereby a
15–29% increase in CD19 expression may not have obvious effects on B
cell function. Given this, autoantibody production in
hCD19TG-4+/- mice (Table II) is even more
remarkable. Thus, the autonomous ability of CD19 to regulate endogenous
kinase activity in B cells may contribute to the development of
autoimmunity when CD19 expression is increased.
CD19 physically associates with CD21, CD81, and Leu-13 on the surface
of B cells (2, 32). Associations between CD19 and CD21 may
explain why both CD19 and CD21 expression levels were higher on B cells
from patients with SSc, while CD20, CD22, and CD40 expression levels
were normal (Figs. 5 and 6). However, increased CD19 expression
correlated most significantly with SSc. Although the changes in CD19
and CD21 expression appear selective and correlated with autoimmunity
in these patients, it would be virtually impossible to prove a cause
and effect relationship in this situation. Nonetheless, the finding
that similar increases in cell surface CD19 expression by SSc patients
(20% increase) and transgenic mice (15–29% increase) results in
autoantibody production (
Figs. 3–6) suggests that CD19 regulation may
be functionally linked with autoantibody production in this human
autoimmune disease. In addition, hCD19TG-1+/+ and
hCD19TG-4+/- mice produced high-titer ANA Abs
(Figs. 3 and 4; Table II) and ANAs are detected in >90% of patients
with SSc (33). Alternatively, increased CD19 expression
and autoantibody production in SSc patients may serve as hallmarks for
linked, yet unrelated genetic changes that predispose to sclerosis.
Both genetic and environmental factors have been implicated in the
origins of SSc and the autoantibodies present in this disease. SSc is
associated with certain MHC class I, II, or III genes
(34), although non-MHC loci have also been implicated
(35). In the "tight-skin" mouse model of human SSc, a
genomic duplication of the fibrillin 1 gene is suggested to cause SSc
susceptibility (36). However, skin sclerosis was not
observed in hCD19TG-1+/+ or
hCD19TG-4+/- mice over a 1-year period (data not
shown). Furthermore, anti-DNA topoisomerase I and anticentromere
Abs, which are highly specific for SSc (23, 33), were not
detected in hCD19TG-4+/- or
hCD19TG-1+/+ mice. This may be explained by
qualitative MHC differences between mice and humans as anti-DNA
topoisomerase I and anticentromere autoantibody production is closely
associated with certain HLA-DR genes (33, 37, 38).
Moreover, it is likely that SSc is a polygenic condition resulting from
combinations of multiple disease susceptibility genes. This may explain
why autoantibodies reacting with various other intracellular
components, such as RNA polymerase (RNP), histones, ssDNA, centriole,
U1RNP, heterogeneous nuclear RNP, U3RNP, ubiquitin, and pyruvate
dehydrogenase complex, are also detected in sera from SSc patients
(26, 39, 40, 41, 42, 43, 44). Nonetheless,
hCD19TG-4+/- mice produced ANA, anti-ssDNA,
antihistone, and RF Abs (Fig. 6), which are present in 30–50% of SSc
patients (40, 44, 45) and patients with other autoimmune
disorders (46). Antihistone Ab production in
hCD19TG-4+/- mice may be significant since
antihistone Abs are detected in 44% of diffuse cutaneous SSc patients,
and the presence of antihistone Abs correlates with severe pulmonary
fibrosis in patients with diffuse cutaneous SSc (40).
Production of anti-spindle pole Abs in some
hCD19TG-4+/- mice may be also significant since
60% of patients with anticentriole Abs are diagnosed with SSc-related
disorders (26, 27, 28). Therefore, high CD19 expression by B
cells from patients with SSc may contribute to the development of
autoantibodies in these patients while other disease characteristics
may be caused by different genetic abnormalities.
The relationship between the induction of autoantibodies and the clinical manifestations of most autoimmune diseases is not clear. This is also true for CD19-overexpressing mice that produce autoantibodies, yet do not demonstrate readily discernible features of human autoimmune disease. Nonetheless, these studies demonstrate that subtle alterations in expression of a single cell surface receptor can lead to autoantibody production. Therefore, it is likely that many of the susceptibility genes that contribute to human autoimmunity represent similar subtle alterations in the expression or function of related regulatory molecules. Although investigators have traditionally regarded lymphocytes as either positive or negative for specific cell surface molecules, these studies reinforce the concept that it may be more important to quantify the amount of each receptor expressed on the surface of cells. Subtle differences in gene dosage or protein expression or function may be particularly important in instances when you are trying to understand the molecular basis for abnormal function of a cell population or surface molecule.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 S.S. and M.H. contributed equally to this study and share first authorship.
3 Address correspondence and reprint requests to Dr. Thomas F. Tedder, Department of Immunology, Box 3010, Duke University Medical Center, Durham, NC 27710.
4 Abbreviations used in this paper: hCD19, human CD19; mCD19, mouse CD19; ANA, antinuclear Ab; hCD19TG, hCD19-transgenic mice; RF, rheumatoid factor; RNP, RNA polymerase; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
Received for publication April 19, 2000. Accepted for publication September 11, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  K. M. Haas, J. C. Poe, and T. F. Tedder CD21/35 Promotes Protective Immunity to Streptococcus pneumoniae through a Complement-Independent but CD19-Dependent Pathway That Regulates PD-1 Expression J. Immunol., September 15, 2009; 183(6): 3661 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iwata, A. Yoshizaki, K. Komura, K. Shimizu, F. Ogawa, T. Hara, E. Muroi, S. Bae, M. Takenaka, T. Yukami, et al. CD19, a Response Regulator of B Lymphocytes, Regulates Wound Healing through Hyaluronan-Induced TLR4 Signaling Am. J. Pathol., August 1, 2009; 175(2): 649 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Abraham, T. Krieg, J. Distler, and O. Distler Overview of pathogenesis of systemic sclerosis Rheumatology, June 1, 2009; 48(suppl_3): iii3 - iii7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tyndall, M. Matucci-Cerinic, and U. Muller-Ladner Future targets in the management of systemic sclerosis Rheumatology, June 1, 2009; 48(suppl_3): iii49 - iii53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yoshizaki, Y. Iwata, K. Komura, F. Ogawa, T. Hara, E. Muroi, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto, et al. CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma Am. J. Pathol., June 1, 2008; 172(6): 1650 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsushita, M. Hasegawa, T. Matsushita, M. Fujimoto, M. Horikawa, T. Fujita, A. Kawasuji, F. Ogawa, D. A. Steeber, T. F. Tedder, et al. Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice J. Immunol., July 1, 2007; 179(1): 698 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwata, F. Ogawa, K. Komura, E. Muroi, T. Hara, K. Shimizu, M. Hasegawa, M. Fujimoto, Y. Tomita, and S. Sato Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress Rheumatology, May 1, 2007; 46(5): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hasegawa, Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis Am. J. Pathol., September 1, 2006; 169(3): 954 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease PNAS, October 18, 2005; 102(42): 15178 - 15183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yan, M. J. Wolff, J. Unternaehrer, I. Mellman, and M. J. Mamula Targeting antigen to CD19 on B cells efficiently activates T cells Int. Immunol., July 1, 2005; 17(7): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Grimaldi, R. Hicks, and B. Diamond B Cell Selection and Susceptibility to Autoimmunity J. Immunol., February 15, 2005; 174(4): 1775 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Asano, M. Fujimoto, N. Yazawa, S. Shirasawa, M. Hasegawa, H. Okochi, K. Tamaki, T. F. Tedder, and S. Sato B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin Mouse Am. J. Pathol., August 1, 2004; 165(2): 641 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Su, X. Li, J. C. Edberg, J. Wu, P. Ferguson, and R. P. Kimberly A Promoter Haplotype of the Immunoreceptor Tyrosine-Based Inhibitory Motif-Bearing Fc{gamma}RIIb Alters Receptor Expression and Associates with Autoimmunity. II. Differential Binding of GATA4 and Yin-Yang1 Transcription Factors and Correlated Receptor Expression and Function J. Immunol., June 1, 2004; 172(11): 7192 - 7199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hase, Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N. Tsuchiya, K. Tokunaga, N. Masawa, M. Azuma, et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex Blood, March 15, 2004; 103(6): 2257 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kess, T. Peters, J. Zamek, C. Wickenhauser, S. Tawadros, K. Loser, G. Varga, S. Grabbe, R. Nischt, C. Sunderkotter, et al. CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis J. Immunol., December 1, 2003; 171(11): 5697 - 5706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. A. Mongini, A. E. Jackson, S. Tolani, R. J. Fattah, and J. K. Inman Role of Complement-Binding CD21/CD19/CD81 in Enhancing Human B Cell Protection from Fas-Mediated Apoptosis J. Immunol., November 15, 2003; 171(10): 5244 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, S.-J. E. Beavitt, K. W. Harder, M. L. Hibbs, and D. M. Tarlinton The Activation and Subsequent Regulatory Roles of Lyn and CD19 After B Cell Receptor Ligation are Independent J. Immunol., December 15, 2002; 169(12): 6910 - 6918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujimoto, J. C. Poe, A. B. Satterthwaite, M. I. Wahl, O. N. Witte, and T. F. Tedder Complementary Roles for CD19 and Bruton's Tyrosine Kinase in B Lymphocyte Signal Transduction J. Immunol., June 1, 2002; 168(11): 5465 - 5476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. HASLER and M. ZOUALI B cell receptor signaling and autoimmunity FASEB J, October 1, 2001; 15(12): 2085 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hasegawa, M. Fujimoto, J. C. Poe, D. A. Steeber, and T. F. Tedder CD19 Can Regulate B Lymphocyte Signal Transduction Independent of Complement Activation J. Immunol., September 15, 2001; 167(6): 3190 - 3200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hasegawa, M. Fujimoto, J. C. Poe, D. A. Steeber, C. A. Lowell, and T. F. Tedder A CD19-Dependent Signaling Pathway Regulates Autoimmunity in Lyn-Deficient Mice J. Immunol., September 1, 2001; 167(5): 2469 - 2478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Youinou and P M Lydyard CD5/ B cells in nonorgan-specific autoimmune diseases: a fresh look Lupus, August 1, 2001; 10(8): 523 - 525. [PDF]
|
|
|
|
 |
|
 M. Fujimoto, J. C. Poe, M. Hasegawa, and T. F. Tedder CD19 Amplification of B Lymphocyte Ca2+ Responses. A ROLE FOR Lyn SEQUESTRATION IN EXTINGUISHING NEGATIVE REGULATION J. Biol. Chem., November 21, 2001; 276(48): 44820 - 44827. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
